Payment overview · 2025
General Payments
$13,343.06
94 reported records · 14 companies
Healthcare provider profile · identity verified
Roberto A Corpus, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · TRAVERSE CITY, MI · NPI 1417995432
Verified facts
What the public records show
CMS Open Payments records show Roberto A Corpus, M.D. received $13,343.06 in general payments during 2025 across 94 reported records.
AngioDynamics, Inc. accounted for 72.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $9,625.00 | 72.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $2,396.22 | 18.0% | 30 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $261.99 | 2.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $226.56 | 1.7% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $212.72 | 1.6% | 16 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $183.58 | 1.4% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $174.88 | 1.3% | 10 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $77.18 | 0.6% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.44 | 0.3% | 2 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $36.67 | 0.3% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $34.87 | 0.3% | 2 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $31.40 | 0.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.86 | 0.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $19.69 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $9,625.00 | 1 |
| Food and Beverage | $2,269.76 | 90 |
| Consulting Fee | $1,250.00 | 1 |
| Travel and Lodging | $198.30 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auryon Laser System 100-120 Vac Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $9,625.00 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $1,890.12 | 17 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $380.21 | 8 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $261.99 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $226.56 | 18 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $212.72 | 16 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $163.40 | 2 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $50.50 | 3 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $48.76 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $45.39 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $41.44 | 2 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $41.29 | 3 | 2025 |
Source payment records
|
|||||
| SABER Normalized: saber |
Device | CORDIS US CORP. | $36.67 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $35.84 | 1 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $35.08 | 2 | 2025 |
Source payment records
|
|||||
| Event Normalized: event |
Device | Philips North America LLC | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $31.79 | 2 | 2025 |
Source payment records
|
|||||
| Visions 014 Normalized: visions 014 |
Device | Philips North America LLC | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Laser service and other Normalized: laser service and other |
Device | Philips North America LLC | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 153 | 69 |
| Cilostazol | Cilostazol | 99 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 36 |
| Repatha Sureclick | Evolocumab | 67 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 34 |
| Xarelto | Rivaroxaban | 44 | 21 |
| Losartan Potassium | Losartan Potassium | 40 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 38 | 17 |
| Ezetimibe | Ezetimibe | 31 | 18 |
| Lisinopril | Lisinopril | 29 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 12 |
| Carvedilol | Carvedilol | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Furosemide | Furosemide | 12 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,343.06 · 94 records | AngioDynamics, Inc. | AREXVY, Auryon Laser System 100-120 Vac, CAMZYOS, CARDIOMEMS, DIAMONDBACK PERIPHERAL, ELIQUIS, ESPRIT, Event, Extended Holter, Flexitouch Plus, IGT Devices Undivided, IV Other, LEQVIO, Laser service and other, Nimbl, ONPATTRO, PERCLOSE PROSTYLE, REPATHA, SABER, SHINGRIX, SUPERA, Senza, Venclose Maven Catheter, Venovo, Visions 014 | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error